Managing diabetes and chronic kidney disease (CKD) requires a comprehensive approach, including lifestyle changes and medications. One promising advancement in recent years is the use of SGLT2 inhibitors, a class of drugs initially developed to lower blood sugar but now recognized for their kidney-protective benefits. In this article, we explore how SGLT2 inhibitors like dapagliflozin can benefit patients with diabetes and kidney disease.

What Are SGLT2 Inhibitors?

SGLT2 (sodium-glucose cotransporter-2) inhibitors are a type of oral medication that lowers blood sugar levels by preventing the kidneys from reabsorbing glucose. Instead, excess sugar is expelled through urine, reducing blood glucose levels naturally without excessive reliance on insulin. Some of the most commonly prescribed SGLT2 inhibitors include:

• Dapagliflozin (Farxiga)
• Empagliflozin (Jardiance)
• Canagliflozin (Invokana)
• Ertugliflozin (Steglatro)

How Do SGLT2 Inhibitors Benefit Kidney Health?

Recent studies have shown that SGLT2 inhibitors do more than just lower blood sugar—they also provide substantial benefits for kidney function. Here’s how:

1. Slows Progression of Kidney Disease

Research, including the DAPA-CKD trial, has demonstrated that dapagliflozin reduces the risk of kidney function decline in both diabetic and non-diabetic CKD patients. The drug helps preserve glomerular filtration rate (GFR), a key marker of kidney function.

2. Reduces Proteinuria (Protein in Urine)

Proteinuria is a sign of kidney damage, often seen in diabetic nephropathy. SGLT2 inhibitors help reduce excess protein in the urine, slowing down kidney deterioration and improving long-term outcomes.

3. Lowers Risk of Kidney Failure and Dialysis

By reducing proteinuria and preserving GFR, SGLT2 inhibitors work to decrease the likelihood of needing dialysis. 

Cardiovascular and Metabolic Benefits

Apart from kidney health, SGLT2 inhibitors provide additional advantages:

• Lowers Blood Pressure: By reducing glucose and sodium reabsorption, these medications lead to improved blood pressure control.
• Weight Management: SGLT2 inhibitors promote weight loss, which is beneficial for diabetic and kidney disease patients.
• Reduces Heart Failure Risk: Patients with CKD and diabetes are at a higher risk of heart failure. Studies have shown that dapagliflozin and empagliflozin reduce hospitalizations due to heart failure.

Who Can Benefit from SGLT2 Inhibitors?

These medications are recommended for:

• Type 2 diabetes patients with kidney disease
• Non-diabetic CKD patients (as per recent guidelines)
• Individuals at risk of kidney failure

However, SGLT2 inhibitors may not be suitable for:

• Patients with severe kidney impairment (eGFR below a certain threshold)
• Those prone to frequent urinary tract infections
• Individuals with low blood pressure or dehydration risk

Are There Any Side Effects?

Like any medication, SGLT2 inhibitors have potential side effects, including:

• Increased urinary tract and genital infections
• Dehydration (due to increased urination)
• Risk of diabetic ketoacidosis (DKA), especially in insulin-dependent diabetics

SGLT2 inhibitors like dapagliflozin (Farxiga) are revolutionizing diabetes and kidney disease management by slowing CKD progression, lowering cardiovascular risks, and improving overall outcomes. If you have diabetes and kidney disease, consult your doctor to see if an SGLT2 inhibitor might be right for you. These medications can be helpful alongside your work with a renal dietitian.